[Preventive treatment of diabetic microangiopathy: blocking the pathogenic mechanisms].
The development of drugs in order to block metabolic pathway of glucose responsible for diabetic vascular dysfunction is in progress. Aldose reductase inhibitors prevent or reduce the different components of vascular dysfunction, cataract, neuropathy and nephropathy in animal models of diabetes. Promising results have been observed in diabetic patients concerning the prevention of neuropathy and of retinopathy. Larger scale studies with the second generation compounds are in progress. Glycation inhibitors, mainly aminoguanidine, have been shown to prevent or reduce vascular dysfunction and microvascular complications in animal models. Trials in diabetic patients with aminoguanidine are just beginning. Anti-oxidant therapy is also at its early stage of development (vitamin E, vitamin C, alpha lipoic acid). Antiplatelet agents (aspirin, ticlopidine) have been demonstrated to reduce the progression of non proliferative diabetic retinopathy. Angiotensin converting enzyme inhibitors are of particular interest in preventing diabetic glomerulopathy.
Guillausseau
P J
PJ
Service de Médecine B, Hôpital Lariboisière, Paris, France.
D000449:Aldehyde Reductase / Q000378:metabolism; D000818:Animals; D003925:Diabetic Angiopathies / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D005947:Glucose / Q000378:metabolism; D006031:Glycosylation; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy*; D010084:Oxidation-Reduction; D011506:Proteins / Q000378:metabolism; D013012:Sorbitol / Q000378:metabolism
D011506:Proteins; D013012:Sorbitol; D000449:Aldehyde Reductase; D005947:Glucose
Traitement préventif de la microangiopathie diabétique: bloquer les mécanismes pathogéniques.